Aileen Deng, Andrew Chapman and Jianqing Lin
Tyrosine kinase inhibitors (TKIs) have emerged as the mainstay treatment for renal cell carcinoma (RCC). Despite growing popularity of TKIs, the treatment safety and tolerability in elderly patients are yet to be fully understood. As new assessment tools become available in identifying elderly patients with cancer at risk for severe treatment-related toxicities, much remains to be learned about how to integrate these tools into our management of elderly patients with cancer. We present a case of a 75- year-old man with RCC who was initially treated with pazopanib and subsequently treated with sunitinib. We review the safety and toxicity profiles of TKIs in treating elderly patients with RCC.
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi